## Phuc Le

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9473906/publications.pdf

Version: 2024-02-01

933264 794469 23 366 10 19 citations h-index g-index papers 23 23 23 544 docs citations citing authors all docs times ranked

#	Article	IF	Citations
1	Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. JAMA Internal Medicine, 2018, 178, 248.	2.6	52
2	Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey. Diabetes Care, 2020, 43, 1227-1233.	4.3	51
3	Herpes zoster infection. BMJ: British Medical Journal, 2019, 364, k5095.	2.4	44
4	Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years. Annals of Internal Medicine, 2015, 163, 489-497.	2.0	42
5	Cost-Effectiveness of Competing Treatment Strategies for <i>Clostridium difficile</i> Infection: A Systematic Review. Infection Control and Hospital Epidemiology, 2018, 39, 412-424.	1.0	30
6	Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. Pharmacoeconomics, 2019, 37, 169-200.	1.7	24
7	Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. Journal of General Internal Medicine, 2017, 32, 159-167.	1.3	15
8	The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. Hepatology International, 2018, 12, 37-43.	1.9	15
9	Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine. JAMA Internal Medicine, 2018, 178, 1277.	2.6	12
10	Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. Expert Opinion on Investigational Drugs, 2020, 29, 205-208.	1.9	12
11	Cost-effectiveness of Haemophilus influenzae type b vaccine in Vietnam. Vaccine, 2015, 33, 4639-4646.	1.7	10
12	Population-Based Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults With Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2019, 17, 2377-2378.	2.4	10
13	Preventing herpes zoster through vaccination: New developments. Cleveland Clinic Journal of Medicine, 2017, 84, 359-366.	0.6	9
14	Post-GAVI sustainability of the Haemophilus influenzae type b vaccine program: The potential role of economic evaluation. Human Vaccines and Immunotherapeutics, 2016, 12, 2403-2405.	1.4	8
15	Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S American Journal of Preventive Medicine, 2017, 53, 829-836.	1.6	8
16	Adherence to the American Diabetes Association's Glycemic Goals in the Treatment of Diabetes Among Older Americans, 2001–2018. Diabetes Care, 2022, 45, 1107-1115.	4.3	8
17	Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults with Prediabetes. Journal of General Internal Medicine, 2019, 34, 2336-2338.	1.3	6
18	Trends in Age at Diagnosis of Type 2 Diabetes Among US Adults from 2001 to 2016. Journal of General Internal Medicine, 2021, 36, 1144-1146.	1.3	3

## Рнис Le

#	Article	IF	CITATIONS
19	Navigating changes in <i>Clostridioides difficile</i> prevention and treatment. Journal of Managed Care & Decialty Pharmacy, 2020, 26, S3-S23.	0.5	3
20	Which shingles vaccine for older adults?. BMJ: British Medical Journal, 2018, 363, k4203.	2.4	2
21	Limited Focus in Evaluation of Vaccine Cost-effectivenessâ€"Reply. JAMA Internal Medicine, 2018, 178, 1564.	2.6	1
22	Association of antibiotic use and acute kidney injury in patients hospitalized with community-acquired pneumonia. Current Medical Research and Opinion, 2022, 38, 443-450.	0.9	1
23	Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes. Journal of General Internal Medicine, 2022, , 1.	1.3	0